161 related articles for article (PubMed ID: 19774328)
1. Reduction in ECG abnormalities and improvement of regional left ventricular function in a patient with Fabry's disease during enzyme-replacement therapy.
Prinz C; Farr M; Hering D; Horstkotte D; Faber L
Clin Res Cardiol; 2010 Jan; 99(1):53-5. PubMed ID: 19774328
[No Abstract] [Full Text] [Related]
2. Many Faces of Fabry's Cardiomyopathy.
Jain R; Kalvin L; Johnson B; Muthukumar L; Khandheria BK; Tajik AJ
JACC Cardiovasc Imaging; 2018 Apr; 11(4):644-647. PubMed ID: 29361493
[No Abstract] [Full Text] [Related]
3. PR interval and the response to enzyme-replacement therapy for Fabry's disease.
Waldek S
N Engl J Med; 2003 Mar; 348(12):1186-7. PubMed ID: 12646684
[No Abstract] [Full Text] [Related]
4. Enzyme replacement therapy for Fabry's disease.
Waldek S; Germain DP; Wanner C; Warnock DG
Lancet; 2010 May; 375(9725):1523; author reply 1523-4. PubMed ID: 20435225
[No Abstract] [Full Text] [Related]
5. Enzyme replacement therapy for Fabry's disease.
Deegan P
Lancet; 2010 May; 375(9725):1522-3; author reply 1523-4. PubMed ID: 20435224
[No Abstract] [Full Text] [Related]
6. Cardiac Fabry's disease: an unusual cause of left ventricular hypertrophy.
Nunes JP; Costa O; Faria Mdo S; Almeida PB; Lacerda L
Nat Clin Pract Cardiovasc Med; 2007 Nov; 4(11):630-3. PubMed ID: 17957210
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Effects of Enzyme Replacement Therapy for Anderson-Fabry Disease.
Tsujiuchi M; Ebato M; Maezawa H; Mizukami T; Nogi A; Ikeda N; Iso Y; Suzuki H
Int Heart J; 2019 Jan; 60(1):208-214. PubMed ID: 30464119
[TBL] [Abstract][Full Text] [Related]
8. Enzyme replacement therapy in Anderson-Fabry's disease: beneficial clinical effect on vital organ function.
De Schoenmakere G; Chauveau D; Grünfeld JP
Nephrol Dial Transplant; 2003 Jan; 18(1):33-5. PubMed ID: 12480957
[TBL] [Abstract][Full Text] [Related]
9. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease.
Spinelli L; Pisani A; Sabbatini M; Petretta M; Andreucci MV; Procaccini D; Lo Surdo N; Federico S; Cianciaruso B
Clin Genet; 2004 Aug; 66(2):158-65. PubMed ID: 15253767
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of replacement enzyme therapy on central nervous system manifestations in Fabry's disease].
Besson G; Vadot W; Guellerin J
Rev Med Interne; 2010 Dec; 31 Suppl 2():S257-9. PubMed ID: 21211675
[TBL] [Abstract][Full Text] [Related]
11. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study.
Madsen CV; Bundgaard H; Rasmussen ÅK; Sørensen SS; Petersen JH; Køber L; Feldt-Rasmussen U; Petri H
Scand Cardiovasc J; 2017 Aug; 51(4):207-216. PubMed ID: 28545342
[TBL] [Abstract][Full Text] [Related]
12. The heart in Anderson Fabry disease.
Kampmann C; Wiethoff CM; Perrot A; Beck M; Dietz R; Osterziel KJ
Z Kardiol; 2002 Oct; 91(10):786-95. PubMed ID: 12395219
[TBL] [Abstract][Full Text] [Related]
13. Myocardial Storage, Inflammation, and Cardiac Phenotype in Fabry Disease After One Year of Enzyme Replacement Therapy.
Nordin S; Kozor R; Vijapurapu R; Augusto JB; Knott KD; Captur G; Treibel TA; Ramaswami U; Tchan M; Geberhiwot T; Steeds RP; Hughes DA; Moon JC
Circ Cardiovasc Imaging; 2019 Dec; 12(12):e009430. PubMed ID: 31826677
[TBL] [Abstract][Full Text] [Related]
14. Genetics and Gene Therapy of Anderson-Fabry Disease.
Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
[TBL] [Abstract][Full Text] [Related]
15. Cardiopulmonary involvement in Fabry's disease.
Koskenvuo JW; Kantola IM; Nuutila P; Knuuti J; Parkkola R; Mononen I; Hurme S; Kalliokoski R; Viikari JS; Wendelin-Saarenhovi M; Kiviniemi TO; Hartiala JJ
Acta Cardiol; 2010 Apr; 65(2):185-92. PubMed ID: 20458826
[TBL] [Abstract][Full Text] [Related]
16. Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease.
Collin C; Briet M; Tran TC; Beaussier H; Benistan K; Bensalah M; Mousseaux E; Froissart M; Bozec E; Laurent S; Boutouyrie P; Germain DP
Eur J Prev Cardiol; 2012 Feb; 19(1):43-54. PubMed ID: 21450622
[TBL] [Abstract][Full Text] [Related]
17. Enzyme replacement in the treatment of Fabry's disease. Is there a point-of-no-return?
del Toro N; Milán JA; Palma A
Nephrol Dial Transplant; 2004 Apr; 19(4):1018. PubMed ID: 15031378
[No Abstract] [Full Text] [Related]
18. [Effect of enzyme replacement therapy (ERT) on renal function of patients with Fabry's disease].
Thomaidis T; Relle M; Reinke J; Beck M; Schwarting A
Med Klin (Munich); 2009 Sep; 104(9):699-703. PubMed ID: 19779674
[TBL] [Abstract][Full Text] [Related]
19. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
[TBL] [Abstract][Full Text] [Related]
20. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy.
Beer M; Weidemann F; Breunig F; Knoll A; Koeppe S; Machann W; Hahn D; Wanner C; Strotmann J; Sandstede J
Am J Cardiol; 2006 May; 97(10):1515-8. PubMed ID: 16679096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
